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A series of six novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes was synthesized
and characterized in detail by elemental analysis, FT-IR, ESI-MS, HPLC, multinuclear (1H, 13C, 15N, 195Pt)
NMR spectroscopy and in one case by X-ray diffraction. Cytotoxic properties of the complexes were
evaluated in four human tumor cell lines originating from ovarian carcinoma (CH1 and SK-OV-3), colon
carcinoma (SW480) and non-small cell lung cancer (A549) by means of the MTT colorimetrical assay. In
addition, their octanol/water partition coefﬁcients (log P values) were determined. Remarkably the most
active (and also most lipophilic) compounds, having 4-propyloxy-4-oxobutanoato and 4-(2-propyloxy)-
4-oxobutanoato axial ligands, showed IC50 values down to the low nanomolar range.
 2011 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
Nowadays, 35 years after the serendipitous discovery of the
cytotoxic potential of cis-diamminedichloridoplatinum(II) [1],
more than 50% of anticancer therapy is platinum based. All plat-
inum containing drugs used in the clinics are platinum(II)
compounds (cisplatin, carboplatin, oxaliplatin, nedaplatin, loba-
platin and heptaplatin) [2]. However, it was shown, that Pt(IV)
complexes also exhibit strong cytotoxic activity and can have some
advantages in comparison to their Pt(II) analogues [3,4]. Conse-
quences of the higher oxidation state are the introduction of two
extra ligands and the change from planar to octahedral geometry.
These characteristics, together with their higher kinetic inertness
compared to their platinum(II) counterparts, opens up new possi-
bilities in the design of novel platinum-based drugs (easier
modulation of the pharmacokinetic properties, more opportunities
for targeted therapy, oral administration, etc.) [5]. Nevertheless, no
Pt(IV) complex has gained clinical approval up to now [2]. Four
Pt(IV) compounds were in clinical trials (Fig. 1): tetraplatin was
rejected after phase I because of a high general toxicity [6]; ipro-
platin was abandoned after phase III clinical trials, because it didn’tax: þ43 1 4277 52680.
(M. Galanski), bernhard.
nder CC BY-NC-ND license.show advantages compared with carboplatin [2]; satraplatin was
rejected after the SPARC (Satraplatin and Prednisone Against
Refractory Cancer) phase III clinical trials [7], because it didn’t show
a convincing beneﬁt in terms of overall survival [8]; currently
satraplatin is in phase I and II clinical trials in combination regi-
mens [9]; its adamantylamine analogue LA-12 has passed phase I
clinical trials.
Considering the mechanism of action of Pt(IV) complexes, it is
accepted that they act as prodrugs via activation by reduction to their
reactive Pt(II) species [10,11]. Pt(IV) based drugs would have better
activity and lower side effects,when they are reduced primarily in the
cell; contrary, an extracellular reduction would lead to deactivation
and general toxicity. Consequently, the drug’s potential strongly
correlateswith the rate of reductionwhich depends on the respective
reductionpotential [12]. Depending on the nature of the axial ligands,
platinum(IV) complexes are reduced more easily in the following
order: CF3COO> Cl> CH3COO>OH [13] It was found that complexes
with Cl as axial ligands were reduced very fast and showed a high
general toxicity (tetraplatin [14]), on the other hand, complexes with
axial hydroxido ligands were not reduced fast enough in the body to
express their antitumor activity (iproplatin [15]). In the case of axial
carboxylato ligands, an intermediate and optimal redox potential was
observed [16], which led to promising results, obtained in preclinical
and clinical evaluation of satraplatin and its adamantylamine
analogue LA-12.
Fig. 1. Chemical structures of anticancer Pt(IV) complexes evaluated in clinical trials.
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ylatoplatinum(IV) complexes and modulation of their physico-
chemical properties such as solubility and lipophilicity was
reported by our group [17e22]. In order to broaden the knowledge
with respect to structureeactivity relationships for that type of
compounds and to ﬁnd candidates with a promising physicochem-
ical and pharmacological proﬁle, we have synthesized a series of
bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes.
The new compoundswere fully characterized by elemental analysis,
ATR IR, multinuclear NMR spectroscopy, HPLC and X-ray crystal-
lography in one of the cases. Their cytotoxic properties were eval-
uated in four human tumor cell lines, originating from ovarian
carcinoma (CH1 and SK-OV-3), colon carcinoma (SW480) and non-
small cell lung cancer (A549), by means of the MTT colorimetrical
assay. In addition, their octanol/water partition coefﬁcients (log P)
were determined.Fig. 2. Synthesis of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes
deg., iii ¼ RONa/ROH, RT, iv ¼ cyclopentylamine/DMF, RT.2. Result and discussion
2.1. Synthesis
The new complexes were prepared according to the reaction
scheme shown in Fig. 2, starting fromK2PtCl4, which was converted
to (SP-4-2)-dichloridobis(ethylamine)platinum(II) (complex 1).
Oxidation of 1 to the dihydroxido complex 2 was performed in
aqueous solution, using 15% hydrogen peroxide as oxidizing agent.
Subsequent carboxylation of 2 with succinic anhydride was
carried out in absolute DMF obtaining the dicarboxylato complex.
The latter was used as starting material for the synthesis of
complexes 4e8 via activation of its free carboxylic groups with CDI
(1,10-carbonyldiimidazole) in absolute DMF under argon atmo-
sphere. To the imidazolide formed in situ, the respective alcoholate/
alcohol mixtures or amine were added to obtain the respective
esters (4e6) or amide (8). Puriﬁcation of the crude products was
performed with column chromatography and re-crystallization,
when necessary.
When synthesizing complex 7 following the described proce-
dure, a mixture of the desired diisopropylester (7) and asymmetric
methylisopropylester (7a) in a ratio of 2:1 (according to 1H NMR)
was obtained. Unfortunately separation and isolation of compound
7was not successful. Formation of the mixed methylisopropylester
derivative 7a was also conﬁrmed by ESI-MS. Most likely 7a was
formed during separation via column chromatography. Apparently,
reaction of 3 after CDI activationwith isopropanol is not as fast as in
the case of complexes 4e6. As a result, the monoimidazolide
platinum complex reacted with methanol, one of the constituents
of the mobile phase. By increasing the reaction time from 24 to 72 h
and avoiding the use of methanol in the mobile phase for puriﬁ-
cation, we were able to obtain exclusively pure 7 in satisfactory
yield.
2.2. Spectroscopic characterization
Structures of the starting compounds (1, 2) were proven by NMR
and ATR IR spectroscopy and the new complexes (3e8) were fully
characterized by elemental analysis, one- and two-dimensionalwith NMR numbering scheme; i ¼ succinic anhydride/DMF, 70 deg., ii ¼ CDI/DMF, 60
Fig. 3. ORTEP diagram of 4 displaying thermal ellipsoids at 50% probability.
Table 1
Selected bond lengths (Å) and bond angles () in complex 4.
Bond lengths (Å)
PteO1 2.039 PteN2 2.068
PteO5 2.039 PteCl1 2.324
PteN1 2.063 PteCl2 2.309
Bond angles (deg)
N1ePt1eO1 86.26 O1ePteO5 172.70
N1ePteN2 92.69 N1ePteCl1 178.18
N2ePteCl1 86.26 N2ePteCl2 175.68
N1ePteCl2 88.72 PteO1eC1eO2 1.87
Cl1ePteCl2 92.22 PteO5eC6eO6 0.45
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troscopy and in the case of 4 also by X-ray diffraction.
Conﬁguration of the novel platinum agents can best be estab-
lished with the help of one- and two-dimensional multinuclear
NMR spectroscopy. 1H and 13C chemical shifts of compounds 1e8
were found in the expected range, proving the supposed structure
of the complexes. Correct assignment of the signals was based on
1H1H COSY, 1H13C HSQC and 1H13C HMBC spectra of the complexes.
In 1H NMR spectra, oxidation and subsequent derivatization can
best be judged according to the shift of the NH2 signal from
5.09 ppm in the Pt(II) complex 1 to 5.96 ppm in the dihydroxido
complex 2, and to 7.85e7.91 ppm in the dicarboxylato complexes
3e8, respectively. Also indicative are the 15N resonances, where the
signal for NH2 shifts from 40.9 ppm in complex 1 to
around 21.3 ppm in compounds 3e8. Additionally, successful
derivatizations of complex 3were observed in 13C NMR spectra. The
resonance of C-6 (uncoordinated COOH) was shifted upﬁeld upon
formation of esters 4e7 or amide 8 by ca. 2 ppm. 195Pt NMR is very
powerful technique for investigating the oxidation state and the
coordination sphere of platinum complexes. 195Pt signals for
complexes 3e8 were detected in the region between 2849 and
2853 ppm, typical for compounds with cis,cis,trans-PtIVCl2N2O2
coordination [23] In comparison, the platinum(II) complex 1 reso-
nates at 601 ppm, more than 3000 ppm upﬁeld to the plati-
num(IV) analogues. As expected, derivatization of 3 had no
inﬂuence on the 195Pt signal, because the changes in the molecule
are far away from the 195Pt nucleus.
Oxidation of 1 and derivatization of 2 can also be followed in the
IR spectra of the complexes. A new and intense signal at 3490 cm1,
corresponding to nPtOeH can be observed in the spectrum of
complex 2, in comparison with that of 1. After esteriﬁcation with
succinic anhydride this signal disappeared and in complexes 3e8
new strong bands in the region 1730e1630 cm1 (nC]O) were
detected, proving the successful carboxylation. In esters 4e7, bands
with 10e25 higher reciprocal wavelengths were detected in
comparison with the complex featuring free carboxylic groups (3).
However, the signal around 1710 cm1 is missing in compound 8,
because of amide formation and a strong band with a shoulder
around 1639 cm1could be observed.
ESI-MS spectra have also conﬁrmed the identity of the
complexes. All new compounds (3e8) were measured in the
positive as well as in the negative ion mode. In the positive ion
mode, the peak assigned to [M þ Naþ]þ displayed the highest
intensity, whereas in the negative ion mode the highest intensity
was detected for [M  Hþ]. However, a peak corresponding to
[M þ Cl], could also be observed in the spectra of esters
(complexes 4e7). The detected m/z values as well as the isotopic
distribution were in accordance with the expected chemical
structures 3e8.
2.3. Crystal structure of complex 4
The result from the X-ray diffraction analysis of 4 is shown in
Fig. 3. Crystal data, data collection parameters and structure-
reﬁnement details are given in the Experimental section. Selected
bond lengths and angles are listed in Table 1. The compound crys-
tallized in the triclinic centrosymmetric space group P1. The Pt(IV)
atom has an octahedral coordination geometry with two ethylamine
and two chlorido ligands in the equatorial plane and two
4-methoxysuccinates coordinated in axial positions. The PteN,
PteCl, and PteO bond lengths (Table 1) are well comparable with
those, observed in structurally similar complexes [17,18]. Angles in
the PtCl2N2O2 octahedron were found between 86.26 and 92.69,
and between 172.70 and 178.18, respectively. The torsion angles
(PteO1eC1eO2, and PteO5eC6eO6) were found to be close to zero.2.4. Cytotoxicity in cancer cell lines
The new compounds were tested in comparison to cisplatin in
four human tumor cell lines, originating from ovarian carcinoma
(CH1, SK-OV-3), colon carcinoma (SW480) and non-small cell lung
cancer (A549) with the help of the colorimetric microculture MTT
assay. Except for CH1 cells, these cell lines are resistant to cisplatin,
showing IC50 values about one order of magnitude higher than that
in CH1 cells. The concentration-effect curves of the tested
complexes are shown in Fig. 4 and the obtained IC50 values are
summarized in Table 2.
Expectedly, the platinum(IV) precursor 3 featuring two COOH
moieties showed the lowest cytotoxicity in all cell lines. In accor-
dance with previously published data [18,19,22], lipophilicity as
well as cellular accumulation are low for such types of complexes.
Conversion of 3 to the corresponding ester derivatives 4e7 has
a signiﬁcant inﬂuence on antiproliferative potency. Whereas
complex 4 is as cytotoxic as cisplatin in the cisplatin-sensitive CH1
cell line, complexes 5e7 are 3 to 17 times more cytotoxic than
cisplatin in the same cell line. An analogous trend was also
observed in cisplatin-resistant A549, SW480 and SK-OV-3 cells.
Parallel to an increasing lipophilicity of the ester residue (Me, Et,
Pr), the IC50 values are decreasing in all cell lines, yielding clear
structureeactivity relationships. The iPr analogue 7 is similar in
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Fig. 4. Concentration-effect curves of complexes (3e8) in CH1 (A), SK-OV-3 (B), SW480 (C) and A549 (D) obtained by the MTT assay (96 h exposure).
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less potent in the other cell lines. In analogy to previous observa-
tions [22], the cyclopentylamide derivative is equipped with a very
low antiproliferative potency, despite its high lipophilicity (see
below).
2.5. Lipophilicity vs. cytotoxicity
As an important factor for the pharmacokinetics and the cellular
accumulation of the new complexes, the lipophilicity was deter-
mined by measuring octanol/water partition coefﬁcients (log P) by
two different methods; log P values, obtained by RP-HPLC and by
the shake-ﬂask method are shown in Table 3.
Complexes 4e8 have signiﬁcantly higher log P values than that
reported for cisplatin (2.59) and platinum(II) complex 1 (1.47)
[24]. However, complex 3 is also more lipophilic than its Pt(II)
congener (1), but its lipophilicity is pH-dependent, due to the
presence of two underivatized carboxylic groups (lower lip-
ophilicity under physiological conditions is expected). In Fig. 5,
a semi-logarithmic graph plotting the cytotoxicity versus log P of
the new complexes is shown. In case of compounds 3e7, a linear
dependency between lipophilicity and cytotoxicity could be
observed e the more lipophilic a complex, the higher itsTable 2
Cytotoxicity of novel complexes (3e8) in comparison to cisplatin in four human
cancer cell lines.
Compound IC50 (mM)a
CH1 A549 SW480 SK-OV-3
3/ReCOOH 5.6  1.6 50  8 40  12 120  17
4/ReCOOMe 0.16  0.05 2.5  0.9 1.0  0.3 2.4  0.1
5/ReCOOEt 0.061  0.015 1.0  0.4 0.30  0.05 1.2  0.3
6/ReCOOPr 0.014  0.002 0.20  0.03 0.11  0.01 0.19  0.03
7/ReCOOiPr 0.0094  0.0012 0.78  0.09 0.39  0.07 0.49  0.11
8/ReCONHR 0.75  0.10 19  3 6.1  0.6 13  1
Cisplatin 0.16  0.03 1.3  0.3 3.5  0.3 1.9  0.3
a 50% Inhibitory concentrations in CH1, A549, SW480 and SK-OV-3 cells in the
MTT assay, 96 h exposure. Values are the means  standard deviations obtained
from three independent experiments.cytotoxicity. The amide complex 8 does not match this trend e
according to its lipophilicity, a higher cytotoxicity would be ex-
pected. The reasons for the latter ﬁnding are yet unclear.2.6. Induction of apoptosis and necrosis
In order to compare the capacities of inducing apoptosis and
necrosis of one representative, namely compound 7, with those of
cisplatin, growing SW480 cultures were treated with these
compounds in various concentrations for 48 h, then double-stained
with annexin V-FITC and propidium iodide and analyzed by
ﬂuorescence-activated cell sorting (FACS). This method allows to
discriminate necrotic (stained by propidium iodide only), early
apoptotic (stained by annexin V-FITC) and late apoptotic (stained
by both) from viable (unstained) cells. From the dot plots (Fig. 6), it
becomes obvious that the apoptosis-inducing potency of
compound 7 is much higher than that of cisplatin. 50 mM of
compound 7 reduce the amount of viable cells to 50% by induction
of both apoptosis (29%) and necrosis (21%), while the same
concentration of cisplatin has very little effect within the chosen
exposure time in the intrinsically cisplatin-resistant SW480 (colon
cancer) cells.Table 3
Log P values for complexes 3e8, R1 and R2, estimated by RP-HPLC and the shake-
ﬂask method.
Compound Log P values, determined by RP-HPLC in different
MeOH concentrations
Log P,
determined
by the
shake-ﬂask
method
0% 10% 20% 30% 40% 50%
R1 1.04 1.03 1.00 0.95 0.99 0.88 0.81
3 0.70 0.84 0.79 0.64 1.14 0.97
4 0.30 0.25 0.17 0.08 0.14 0.10 0.12
5 0.90 0.87 0.83 0.73 0.78 0.85 0.64
6 1.38 1.41 1.44 1.49 1.47 1.48 1.44
7 1.30 1.33 1.36 1.41 1.37 1.39
8 1.11 1.14 1.17 1.23 1.20 1.25 1.21
R2 1.39 1.41 1.44 1.48 1.44 1.46 1.69
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Fig. 5. Semi-logarithmic plot of lipophilicity (log P determined with RP-HPLC) of complexes 3e8 vs. cytotoxicity (IC50) in CH1, A549, SW480 and SK-OV-3 cells.
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is a powerful apoptotic agent, which effectively causes cell death in
a dose-dependent way.
3. Conclusions
Six novel bis(carboxylato)platinum(IV) complexes have been
synthesized and fully characterized. The new compounds were
investigated for their lipophilic properties and their in vitro cyto-
toxicity in four human tumor cell lines. Remarkably, IC50 values
down to the nanomolar range, up to 32 times lower compared to
cisplatin, were found. Whether the very high cytotoxicity is also
accompanied by manageable systemic toxicity in vivo will be
evaluated in future work.Fig. 6. FACS analysis of annexin V- and PI-stained SW480 colon cancer cells. Left column: u
48 h. The upper left quadrant contains the necrotic (stained by PI only), the lower right earl
both) and the lower left quadrant the viable (unstained) fraction of cell populations.4. Experimental protocols
4.1. Materials and methods
All reagents and solvents were obtained from commercial
suppliers, and were used without further puriﬁcation. Methanol
and ethanol were dried, according to standard procedures. For
column chromatography, silica gel 60 (Fluka) was used. (OC-6-33)-
Dichloridobis(ethylamine)dihydroxidoplatinum(IV) (complex 2,
Fig. 2) was synthesized starting from K2PtCl4 and ethylamine, using
Dhara’s [25] method with some modiﬁcations. The resulting
dichlorido complex 1 was oxidized with 15% H2O2.
1H, 13C, 15N, 195Pt and two-dimensional 1H1H COSY, 1H13C and
1H15N HSQC, and 1H13C HMBC NMR spectra were recorded withntreated control; right column: after treatment with 50 mM cisplatin/compound 7 for
y apoptotic (stained by annexin V-FITC only), the upper right late apoptotic (stained by
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Fig. 7. Concentration-effect curves for compound 7 (A) and cisplatin (B) with regard to
apoptosis and necrosis induction in SW480 cells after 48 h exposure, measured by
FACS using annexin V-FITC/propidium iodide staining.
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125.81 (13C), 107.55 (195Pt), and 50.70 MHz (15N) in DMF-d7 at
ambient temperature, using the solvent residual peak for 1H and
13C as internal reference. The splitting of proton resonances in the
1H NMR spectra are deﬁned as s ¼ singlet, bs ¼ broad singlet,
d¼ doublet, t¼ triplet, and m¼multiplet. 15N chemical shifts were
referenced relative to external NH4Cl; whereas 195Pt chemical shifts
were referenced relative to external K2[PtCl4] (see Fig. 2 for NMR
numbering scheme).
IR spectra were obtained with a PerkineElmer 370 FT-IR 2000
instrument (4000e400 cm1) by using an ATR unit. Intensities of
reported IR bands are deﬁned as br ¼ broad, s ¼ strong,
m ¼ medium, and w ¼ weak. Electrospray ionization mass spec-
trometry was carried out with a Bruker Esquire 3000 instrument
using MeOH as solvent. Elemental analyses were performed with
a PerkineElmer 2400 CHN-Elemental Analyzer by the Microana-
lytical Laboratory of the University of Vienna. Analyses indicated by
the symbols of the elements or functions were within 0.4% of the
theoretical values. Purity of novel compounds was additionally
proved by analytical reversed-phase HPLC.4.2. Synthesis
4.2.1. (OC-6-33)-Bis(3-carboxypropanoato)dichloridobis(ethylamine)-
platinum(IV) (3)
Succinic anhydride (674.3 mg, 6.738 mmol) and 653 mg
(1.675 mmol) of (OC-6-33)-dichloridobis(ethylamine)dihydrox-
idoplatinum(IV) were suspended in 9 mL of absolute DMF and the
reaction mixture was stirred at 65 C for 40 min and then for 2
more hours at room temperature. During this time, the solidmaterial dissolved to form a yellow-brown solution. DMF was
removed under reduced pressure. The residue was dissolved in
acetone and ﬁltered to give a clear, yellow solution. This solution
was concentrated under reduced pressure, and subsequent
addition of diethyl ether led to precipitation of a pale yellow solid.
The precipitate was ﬁltrated and dried in vacuo, while heating at
40 C. Yield: 398 mg (40%). Anal. C12H24Cl2N2O8Pt (C, H, N). ESI-
MS: m/z 612.6 [M þ Naþ]þ, 588.7 [M  Hþ]. 1H NMR: d ¼ 12.52
(bs, 2H, COOH), 7.87 (bs, 4H, NH2), 3.10 (m, 4H, H-2), 2.75 (m, 4H,
H-4), 2.68 (m, 4H, H-5), 1.44 (t, 3JH,H ¼ 7.2 Hz, 6H, H-1) ppm. 13C
NMR: d ¼ 181.3 (C-3), 174.1 (C-6), 39.9 (C-2), 31.2 (C-4), 29.9 (C-5),
14.3 (C-1) ppm. 15N NMR7: d ¼ 21.2 ppm. 195Pt NMR:
d ¼ 2851 ppm. IR (ATR): 3241 m, 3197 br; 2977 br; 1710 s (nC]O),
1642 m (nC]O); 1357 m, 1344 m; 1238 s 1216 m, 1175 m; 1081 w,
1024 w (nCeN) cm1.
4.2.2. (OC-6-33)-Dichloridobis(ethylamine)bis((4-methoxy)-4-
oxobutanoato)platinum(IV) (4)
CDI (241.1 mg, 1.4869 mmol) in absolute DMF (10 mL) was
added to a solution of 3 (433.4 mg, 0.7342 mmol) in absolute DMF
(6 mL), and the mixture was heated to 60 C. After 10 min of being
stirred, the solution was cooled to room temperature and CO2 was
removed by ﬂushing with argon. Sodium methanolate (a piece of
Na in 10 mL of absolute MeOH) in absolute MeOH was added and
the solution was stirred for 24 h at room temperature. Methanol
and DMF were removed under reduced pressure to form a yellow
oil. The crude product was puriﬁed by column chromatography
(EtOAc/MeOH, 7:1) to yield a yellow solid, which was dried in
vacuo. Yield: 106 mg (23%). Anal. C14H28Cl2N2O8Pt (C, H, N). ESI-MS:
m/z 640.8 [M þ Naþ]þ, 616.5 [M  Hþ], 652.8 [M þ Cl]. 1H NMR:
d ¼ 7.85 (bs, 4H, NH2), 3.82 (s, 6H, H-7), 3.10 (m, 4H, H-2), 2.78 (m,
4H, H-4), 2.71 (m, 4H, H-5), 1.45 (t, 3JH,H ¼ 7.2 Hz, 6H, H-1) ppm. 13C
NMR: d ¼ 181.0 (C-3), 173.1 (C-6), 51.2 (C-7), 39.9 (C-2), 31.1
(3JC,Pt¼ 38.2 Hz, C-4), 29.8 (C-5),14.3 (3JC,Pt¼ 35.0 Hz, C-1) ppm. 15N
NMR: d ¼ 21.3 ppm. 195Pt NMR: d ¼ 2853 ppm. IR (ATR): 3221 w,
3188 m; 2894 br; 1729 s (nC]O), 1647 s (nC]O); 1362m 1333s; 1259
s, 1198s, 1176 s; 1088 m, 1026 w (nCeN); 683 w cm1. Crystals,
suitable for X-ray data collection, were obtained after vapor diffu-
sion of diethyl ether into a methanol solution of 4.
4.2.3. (OC-6-33)-Dichloridobis((4-ethoxy)-4-oxobutanoato)-
bis(ethylamine)platinum(IV) (5)
The synthesis was carried out as described for 4. The crude
product was puriﬁed by column chromatography (EtOAc/MeOH,
9:1), then recrystallized from ethyl acetate and diethyl ether to
yield a pale yellow solid. The ﬁnal product was dried in vacuo.
Yield: 24 mg (16%). Anal. C16H32Cl2N2O8Pt (C, H, N). ESI-MS: m/z
669.1 [M þ Naþ]þ, 644.3 [M  Hþ], 681.0 [M þ Cl]. 1H NMR:
d ¼ 7.86 (bs, 4H, NH2), 4.26 (m, 3JH,H ¼ 7.1 Hz, 4H, H-7), 3.10 (m, 4H,
H-2), 2.77 (t, 4H, H-4), 2.69 (t, 4H, H-5), 1.45 (t, 3JH,H¼ 7.2 Hz, 6H, H-
1), 1.39 (t, 3JH,H ¼ 7.1 Hz, 6H, H-8) ppm. 13C NMR: d ¼ 181.0 (C-3),
172.7 (C-6), 60.2 (C-7), 39.9 (C-2), 31.1 (3JC,Pt¼ 37.3 Hz, C-4), 30.0 (C-
5), 14.4 (3JC,Pt ¼ 34.5 Hz, C-1), 14.0 (C-8) ppm. 15N NMR:
d¼21.3 ppm. 195Pt NMR: d¼ 2850 ppm. IR (ATR): 3180w, 3153w;
2987 w; 1727 s (nC]O); 1658 m, 1631 m (nC]O); 1369 m; 1260 s,
1231 s; 1163 s; 1085 w; 1039 m, 1023 s (nCeN); 857 w, 681 m cm1.
4.2.4. (OC-6-33)-Dichloridobis(ethylamine)bis((4-propyloxy)-4-
oxobutanoato)platinum(IV) (6)
The synthesis was carried out as described for 4. The crude
product was puriﬁed by column chromatography (EtOAc/MeOH,
11:1), then recrystallized from ethyl acetate and diethyl ether to
yield a pale yellow solid. The ﬁnal product was dried in vacuo.
Yield: 33 mg (11%). Anal. C18H36Cl2N2O8Pt (C, H, N). ESI-MS: m/z
697.1 [M þ Naþ]þ, 672.9 [M  Hþ], 708.9 [M þ Cl]. 1H NMR:
Table 4
Crystallographic data for complex 4.
4
Empirical formula C14H28Cl2N4O8Pt
Fw 618.37
Space group P1
a [Å] 6.0519(3)
b [Å] 13.1190(6)
c [Å] 14.0840(5)
a [] 79.521(2)
b [] 83.694(2)
g [] 85.073(3)
V [Å3] 1090.41(8)
Z 2
l [Å] 0.71073
rcalcd [g cm3] 1.883
Crystal size [mm3] 0.20  0.13  0.12
T [K] 100(2)
m [mm1] 6.719
R1
a 0.0357
wR2
b 0.0858
GOFc 0.989
a R1 ¼ SjjFoj  jFcjj/SjFoj.
b wR2 ¼ {S[w(Fo2  Fc2)2]/S[w(Fo2)2]}1/2.
c GOF ¼ {S[w(Fo2  Fc2)2]/(n  p)}1/2, where n is the number of
reﬂections and p is the total number of parameters reﬁned.
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H-2), 2.78 (m, 4H, H-4), 2.71 (m, 4H, H-5),1.80 (m, 3JH,H¼ 7.3 Hz, 4H,
H-8), 1.44 (t, 3JH,H ¼ 7.2 Hz, 6H, H-1), 1.09 (t, 3JH,H ¼ 7.4 Hz, 6H, H-9)
ppm. 13C NMR: d ¼ 181.0 (C-3), 172.7 (C-6), 65.8 (C-7), 39.9 (C-2),
31.1 (3JC,Pt ¼ 31.1 Hz, C-4), 29.9 (C-5), 22.0 (C-8), 14.4
(3JC,Pt ¼ 34.7 Hz, C-1), 10.1 (C-9) ppm. 15N NMR: d ¼ 21.4 ppm.
195Pt NMR: d ¼ 2850 ppm. IR (ATR): 3222 m, 3192 m; 2970 w; 1731
s (nC]O); 1671 m, 1654 s (nC]O); 1370 m, 1326 m; 1164 s, 1088 w;
684 w cm1.
4.2.5. (OC-6-33)-Dichloridobis(ethylamine)bis((4-(2-propyloxy))-
4-oxobutanoato)platinum(IV) (7)
CDI (184 mg, 1.135 mmol) in absolute DMF (6 mL) was added to
a solution of 3 (325 mg, 0.551 mmol) in absolute DMF (5 mL), and
the mixture was heated to 70 C. After 10 min of being stirred, the
solution was cooled to room temperature and CO2 was removed by
ﬂushing with argon. 12 mL of sodium 2-propanolate (a piece of Na
dissolved in 2-propanol, HPLC grade) was added to the solution and
heated to 40 C. The mixture was then stirred for 72 h at room
temperature. 2-Propanol and DMF were removed under reduced
pressure to form a yellow oil. The crude product was puriﬁed by
column chromatography (EtOAc/2-propanol, 10:1) and then
precipitated with Et2O and cooled to 0 C to give an almost white
solid, which was dried in vacuo. Yield: 110 mg (30%). Anal.
C18H36Cl2N2O8Pt (C, H, N). ESI-MS: m/z 696.8 [M þ Naþ]þ, 673.4
[M  Hþ], 708.8 [M þ Cl]. 1H NMR: d ¼ 7.70 (bs, 4H, NH2), 4.93
(m, 3JH,H ¼ 6.3 Hz, 2H, H-7), 2.94 (m, 4H, H-2), 2.59 (m, 4H, H-4),
2.49 (m, 4H, H-5), 1.27 (t, 3JH,H ¼ 7.2 Hz, 6H, H-1), 1.21 (d,
3JH,H ¼ 6.3 Hz, 12H, H-8) ppm. 13C NMR: d¼ 180.9 (C-3), 172.0 (C-6),
67.4 (C-7), 39.8 (C-2), 30.9 (3JC,Pt ¼ 37.5 Hz, C-4), 30.1(C-5), 21.3 (C-
8), 14.2 (3JC,Pt ¼ 32.9 Hz, C-1) ppm. 15N NMR: d ¼ 21.3 ppm. 195Pt
NMR: d ¼ 2850 ppm. IR (ATR): 3282 m, 3206 m; 2981 w, 2937 w;
1722 s, 1702 s (nC]O); 1668 s, 1637 s (nC]O); 1375 m, 1362 m; 1304
s, 1265 s, 1239s; 1106 m, 1087 m cm1.
4.2.6. (OC-6-33)-Dichloridobis((4-cyclopentylamino)-4-oxobuta-
noato)bis(ethylamine)platinum(IV) (8)
CDI (106.5 mg, 0.6568 mmol) in absolute DMF (7 mL) was added
to a solution of 3 (184.5 mg, 0.3126 mmol) in absolute DMF (5 mL),
and the mixture was heated to 60 C. After 10 min of being stirred,
the solutionwas cooled to room temperature and CO2was removed
by ﬂushing with argon. Cyclopentylamine (75 mL, 0.7516 mmol) in
4 mL of absolute DMFwas added to the solution and stirred for 30 h
in the dark at room temperature. DMF was removed under reduced
pressure to form a brown oil. The crude product was puriﬁed by
column chromatography (EtOAc/MeOH, 4:1) and then precipitated
with Et2O (ultrasonic) and cooled to 0 C to give an almost white
solid, which was ﬁltered off, washed with Et2O and EtOAc and dried
in vacuo. Yield: 64 mg (28%). Anal. C22H42N4O6PtCl2 (C, H, N). ESI-
MS: m/z 747.3 [M þ Naþ]þ, 723.1 [M  Hþ]. 1H NMR: d ¼ 7.95 (d,
3JH,H ¼ 6.9 Hz, 2H, NH-amide), 7.91 (bs, 4H, NH2), 4.26 (m,
3JH,H¼ 6.8 Hz, 2H, H-7), 3.13 (m, 4H, H-2), 2.68 (m, 4H, C-4), 2.56 (m,
4H, H-5), 2.00 (m, 4H, H-8), 1.84 (m, 4H, H-9), 1.70 (m, 4H, H-9), 1.62
(m, 4H, H-8), 1.45 (t, 3JH,H ¼ 7.1 Hz, 6H, H-1) ppm. 13C NMR:
d¼ 181.8 (C-3), 171.3 (C-6), 51.0 (C-7), 40.0 (C-2), 32.7 (C-8), 32.1 (C-
4), 31.8 (C-5), 23.8 (C-9),14.4 (C-1) ppm. 15N NMR: d¼ 107.7 (CONH-
amide),20.3 (NH2) ppm. 195Pt NMR: d¼ 2489 ppm. IR (ATR): 3352
m, 3210 br, 3073 br; 2871 w; 1639 s (nC]O); 1535 s, 1356w,1258m,
1246 w cm1.
4.3. Crystallographic structure determination
X-ray diffraction measurement was performed on a Bruker X8
APEXII CCD diffractometer. Single crystal of 4 was positioned at
40 mm from the detector, and 1839 frames were measured, eachfor 20 s over 1 scan width. The data were processed using SAINT
software [26]. Crystal data, data collection parameters, and
structure-reﬁnement details are given in Table 4. The structures
were solved by direct methods and reﬁned by full-matrix least-
squares techniques. Non-H atoms were reﬁned with anisotropic
displacement parameters. H atoms were inserted in calculated
positions and reﬁned with a riding model. The isotropic thermal
parameters were estimated to be 1.2 times the values of the
equivalent isotropic thermal parameters of the atoms to which
hydrogens were bonded. Structure solution was achieved with
SHELXS-97 and reﬁnement with SHELXL-97 [27], and graphics
were produced with ORTEP-3 [28].
4.4. Determination of lipophilicity
Lipophilicity of new complexes was determined by the shake-
ﬂask method and by reversed-phased HPLC.
4.4.1. Shake-ﬂask method
The log P determination of compounds (4, 5, 6 and 8) was
carried out, according to the guidelines for the shake-ﬂask method
[29] with slight modiﬁcations [20]. Weighted amounts of platinum
complexes were dissolved in HPLC-grade water, which was pre-
saturated with n-octanol, and mixed by sonication for 5 min.
Afterward, the solutions were centrifuged for 5 min and the
concentration of Pt was determined by ICP-MS. Weighted amounts
of that solutions were mixed with the same volume of n-octanol
(pre-saturated with water) and shaken for 15. After phase separa-
tion, the Pt concentration in the aqueous phase was again deter-
mined by ICP-MS and the partition coefﬁcients were calculated.
The platinum content in the aqueous phase was determined by
ICP-MS (Agilent 7500ce, Waldbronn, Germany), equipped with
a CETAC ASX-520 autosampler (Neuss, Germany), a Scott double
pass spray chamber, and aMicroMist nebulizer. For the analysis, the
samples were diluted 1:1000 with 2.5% HCl. Every sample con-
tained 0.5 ppb In as internal standard (CPI International, Santa Rosa,
CA, USA).
4.4.2. Reversed-phase HPLC method
HPLC analysis was performed on a Dionex Summit system
controlled by the Dionex Chromeleon 6.60 software. The
Table 6
Viable, apoptotic and necrotic cell fractions (in %) of SW480 cells upon treatment
with cisplatin or compound 7 for 48 h, analyzed by FACS using annexin V and PI
staining.
Concentration, mM Viable cells Early
apoptosis
Late
apoptosis
Necrosis
Compound 7 (in %)
0 98.3  0.6 0.7  0.3 0.8  0.5 0.2  0.1
5 97.2  1.2 1.5  0.8 1.0  0.4 0.4  0.3
10 87.9  9.8 3.3  1.9 5.1  5.0 3.8  3.7
15 77.7  8.3 3.9  2.9 10.6  5.9 7.9  2.6
25 62.4  4.9 5.8  4.9 14.7  6.2 17.1  7.8
50 47.5  2.6 4.8  0.8 26.3  8.0 21.5  7.0
Cisplatin (in %)
0 98.1  0.7 0.7  0.6 0.5  0.4 0.7  0.5
5 96.1  2.1 1.0  0.2 1.1  0.7 1.9  2.2
10 93.5  2.0 2.5  0.8 1.5  1.2 2.5  3.1
15 95.9  1.0 2.9  0.3 1.0  0.6 0.2  0.1
25 94.9  3.5 3.3  3.4 1.3  0.6 0.6  0.5
50 93.8  3.5 3.7  2.6 1.6  0.8 0.9  0.7
100 78.7  11.3 8.0  3.5 4.6  4.0 8.7  4.7
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column (4.6 mm  250 mm); 0.1% TFA water/MeOH based mobile
phases; UVevis detection set up at 210 nm; temperature of the
column: 25 C; ﬂow rate: 1 mL min1; concentration of the inves-
tigated complexes: 2.5 mM, (1 mM KI as internal standard was
added); 25 mL injection volume. The capacity factors k0 ¼ (tR t0)/t0
(tR is the retention time of the species analyzed and k0 is the reten-
tion time of the unretained substance, used as a standard (here KI))
of the investigated compounds were determined at different
MeOH/water ratios (from 60:40 for the most lipophilic to 10:90 for
the most hydrophilic compounds). Using the linear relationship
between log k’ and the percentage ofMeOH in themobile phase: log
k0 ¼ log k0we %MeOH. log k0 values for all complexeswere calculated
for 0,10, 20, 30, 40 and 50% ofMeOH in themobile phase. Complexes
3e8 and for comparison (OC-6-33)-dichlorido(ethane-1,2-diamine)-
bis{(4-methoxy)-4-oxobutanoato}platinum(IV) (R1) and (OC-6-33)-
bis{(5-butyloxy)-5-oxo-3-methylpentanoato}dichlorido(ethane-1,
2-diamine)platinum(IV) (R2) described in Ref. [22] were investi-
gated. Calibration curves for different MeOH concentrations were
created on the basis of determined log P values of 4-6, 8, R1, and R2.
The equations derived from the calibration curves for different
percentage of MeOH together with their R2 values, are shown in
Table 5. From these equations log P values for all investigated
complexes were calculated.
4.5. Cell lines and culture conditions
CH1 (ovarian carcinoma, human) cells were donated by Lloyd R.
Kelland (CRC Center for Cancer Therapeutics, Institute of Cancer
Research, Sutton, U.K.). A549 (non-small cell lung cancer, human)
and SW480 (colon carcinoma, human) cells were kindly provided
by Brigitte Marian (Institute of Cancer Research, Department of
Medicine I, Medical University of Vienna, Austria), and SK-OV-3
(ovarian carcinoma, human) cells by Evelyn Dittrich (General
Hospital, Medical University of Vienna, Austria). Cells were grown
in 75 cm2 culture ﬂasks (Iwaki/Asahi Technoglass) as adherent
monolayer cultures in Minimal Essential Medium (MEM) supple-
mented with 10% heat-inactivated fetal bovine serum, 1 mM
sodium pyruvate, and 2 mM L-glutamine (all purchased from Sig-
maeAldrich) without antibiotics. Cultures were maintained at
37 C in a humidiﬁed atmosphere containing 5% CO2 and 95% air.
4.6. Cytotoxicity tests in cancer cell lines
Cytotoxicity in the cell lines mentioned above was determined
by the colorimetric MTT assay (MTT ¼ 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, purchased from
Fluka). Cells were harvested from culture ﬂasks by trypsinization
and seeded in 100 mL aliquots in MEM supplemented with 10%
heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 2 mM
L-glutamine, and 1% non-essential amino acids (100) into 96-well
microculture plates (Iwaki/Asahi Technoglass) in the following
densities, to ensure exponential growth of untreated controlsTable 5
Results from the calibration curves log P ¼ f (log k0) under different experimental
conditions.
%MeOH Equation R2
0 0.8842 2.1484 0.92
10 0.9126 1.6351 0.93
20 0.9586 1.1251 0.95
30 0.9736 0.4783 0.98
40 1.0174 þ0.081 0.96
50 1.0063 þ0.7582 0.98throughout the experiment: 1.5  103 (CH1), 3.5  103 (SK-OV-3),
4.0  103 (A549), and 2.5  103 (SW480) viable cells per well. Cells
were allowed to settle and resume exponential growth in drug-free
complete culture medium for 24 h, followed by the addition of
dilutions of the test compounds in 100 mL/well of the same
medium. After continuous exposure for 96 h, the medium was
replaced by a 100 mL/well RPMI 1640 medium (supplemented with
10% heat-inactivated fetal bovine serum and 4 mM L-glutamine)
plus 20 mL/well solution of MTT in phosphate-buffered saline
(5 mg/mL) (all purchased from SigmaeAldrich). After incubation
for 4 h, medium/MTT mixtures were removed, and the formazan
product formed by viable cells was dissolved in DMSO (150 mL/
well). Optical densities at 550 nmweremeasuredwith amicroplate
reader (Tecan Spectra Classic), using a reference wavelength of
690 nm to correct for unspeciﬁc absorption. The quantity of viable
cells was expressed as percentage of untreated controls, and 50%
inhibitory concentrations (IC50) were calculated from
concentration-effect curves by interpolation. Evaluation is based on
means from three independent experiments, each comprising six
replicates per concentration level.4.7. Apoptosis/necrosis assay
Cell death was analyzed by ﬂuorescence-activated cell sorting
(FACS) using FITC-conjugated annexin V (BioVision, USA) and pro-
pidium iodide (PI; Fluka) staining (Table 6).
SW480 cells were seeded into 6-well plates (Iwaki/Asahi Tech-
noglass, Gyouda, Japan) in amounts of 2  105 cells per well in
completemedium(as described above) and allowed to settle for 24 h.
The cells were exposed to cisplatin and compound 7 for 48 h at 37 C.
After the incubation, cells were gently trypsinized, washed with PBS,
and suspended with FITC-conjugated annexin V (0.25 mg/mL) in
binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2) at room temperature for 15 min. PI (1 mg/mL) was added
shortly before the measurement. Stained cells were analyzed with
a FACSCalibur instrument (BectonDickinson, Franklin Lakes,NJ, USA)
using Cell-QuestPro software. At least three independent experi-
ments were conducted, and 10,000 cells were counted per analysis.Acknowledgments
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